Neurodegenerative Diseases

Rosas I.a· Morís G.b,c· Coto E.a,c· Blázquez M.b,c· Suárez E.b,c· García-Fernández C.b,c· Siso P.b· Martínez C.c,d· Pérez-Oliveira S.a· Álvarez V.a,c· Menéndez-González M.b,c

Author affiliations

aLaboratorio de Genética, Hospital Universitario Central de Asturias, Oviedo, Spain
bServicio de Neurología, Hospital Universitario Central de Asturias, Oviedo, Spain
cInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
dServicio de Neurología, Hospital Universitario de Cabueñes, Gijón, Spain

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 18, 2021
Accepted: October 18, 2021
Published online: October 21, 2021
Issue release date: Published online first

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 3

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: https://www.karger.com/NDD

Abstract

Background: Many evidences suggest a pathological link between neurodegenerative diseases and cancer. In fact, several epidemiologic studies indicate a decreased incidence of most cancer types in Parkinson’s disease (PD) patients and some PD genes are involved in cancer networks. Objective: The aim of this study is to assess the influence of several factors in the risk of cancer in a cohort of 753 PD patients and to study how these variables interact with each other. Methods: We analyzed the effect of gender, tobacco, alcohol, type of PD (genetic or idiopathic PD), and two genetic variants, previously associated with cancer, rs5848-GRN and rs1042522-TP53. Results: A higher age at PD onset was observed in patients who develop cancer before PD (p < 0.001). Alcohol consumption was a risk factor to develop cancer in PD patients (p = 0.011), while smoking was not a cancer risk factor in our cohort (p = 0.098). Among the genetic factors, the genotype TT GRN-rs5848 was statistically more frequent in PD patients without cancer (p = 0.05). Conclusions: Our study identified several factors, genetic and nongenetic, which contribute to the risk for cancer in PD.

© 2021 S. Karger AG, Basel

References Koros C, Simitsi A, Stefanis L. Genetics of Parkinson’s disease: genotype-phenotype correlations. Int Rev Neurobiol. 2017;132:197–231. Paul KC, Chuang YH, Shih IF, Keener A, Bordelon Y, Bronstein JM, et al. The association between lifestyle factors and Parkinson’s disease progression and mortality. Mov Disord. 2019 Jan;34(1):58–66. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–72. Tacik P, Curry S, Fujioka S, Strongosky A, Uitti RJ, van Gerpen JA, et al. Cancer in Parkinson’s disease. Parkinsonism Relat Disord. 2016 Oct;31:28–33. Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, et al. Chromosomal amplification of leucine-rich repeatkinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal andthyroid carcinomas. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1439–44. Liu J, Zhang C, Wu H, Sun XX, Li Y, Huang S, et al. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. J Clin Invest. 2020 Jun 1;130(6):3253–69. Agalliu I, Ortega RA, Luciano MS, Mirelman A, Pont-Sunyer C, Brockmann K, et al. Cancer outcomes among Parkinson’s disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson’s disease patients, and nonaffected controls. Mov Disord. 2019 Sep;34(9):1392–8. Xiong D, Wang Y, Kupert E, Simpson C, Pinney SM, Gaba CR, et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet. 2015 Feb 5;96(2):301–8. Duplan E, Giordano C, Checler F, Alves da Costa C. Direct α-synuclein promoter transactivation by the tumor suppressor p53. Mol Neurodegener. 2016 Feb 2;11:13. Li G, Dong T, Yang D, Gao A, Luo J, Yang H, et al. Progranulin promotes lymphangiogenesis through VEGF-C and is an independent risk factor in human esophageal cancers. Hum Pathol. 2018 May;75:116–24. Yang J, Wu X, Huang J, Chen Z, Huang G, Guo X, et al. TP53 polymorphism contributes to the susceptibility to bipolar disorder but not to schizophrenia in the Chinese Han population. J Mol Neurosci. 2019 Aug;68(4):679–87. Nalls MA, Blauwendraat C, Sargent L, Vitale D, Leonard H, Iwaki1 H, et al. Evidence for GRN as part of a neuroinflammatory mechanism connecting common neurodegenerative diseases. medRxiv. 2020. Epub ahead of print. Rademakers R, EriksenRobinson JLT, Baker M, Robinson T, Ahmed Z, Lincoln SJ, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet. 2008;117(23):3631–42. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591–601. De la Casa-Fages B, Fernández-Eulate G, Gamez J, Barahona-Hernando R, Morís G, García-Barcina M, et al. Parkinsonism and spasticparaplegia type 7: expanding the spectrum of mitochondrial Parkinsonism. Mov Disord. 2019 Oct;34(10):1547–61. Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al.; REDECAN Working Group. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017 Jul;19(7):799–825. Voshtani R, Song M, Wang H, Li X, Zhang W, Tavallaie MS, et al. Progranulin promotes melanoma progression by inhibiting natural killer cell recruitment to the tumor microenvironment. Cancer Lett. 2019 Nov 28;465:24–35. Article / Publication Details

First-Page Preview

Received: May 18, 2021
Accepted: October 18, 2021
Published online: October 21, 2021
Issue release date: Published online first

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 3

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: https://www.karger.com/NDD

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.